tradingkey.logo

Outlook Therapeutics Provides Regulatory Update On U.S. FDA Review Of Lytenava

ReutersDec 31, 2025 10:36 PM

- Outlook Therapeutics Inc OTLK.O:

  • OUTLOOK THERAPEUTICS PROVIDES REGULATORY UPDATE ON U.S. FOOD AND DRUG ADMINISTRATION REVIEW OF ONS-5010/LYTENAVA™ (BEVACIZUMAB-VIKG) FOR THE TREATMENT OF WET AMD

  • OUTLOOK THERAPEUTICS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR ONS-5010 BLA

  • OUTLOOK THERAPEUTICS INC: CURRENTLY EXPLORING ALL AVAILABLE PATHWAYS FOR POTENTIAL APPROVAL IN U.S

  • OUTLOOK THERAPEUTICS INC - FDA RECOMMENDS CONFIRMATORY EVIDENCE FOR ONS-5010 APPROVAL

  • OUTLOOK THERAPEUTICS INC: FDA HAS NOT INDICATED WHAT TYPE OF CONFIRMATORY EVIDENCE WOULD BE ACCEPTABLE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI